Vanda Pharmaceuticals | VNDA - Trade Creditors


Vanda Pharmaceuticals reported $39.09M in Trade Creditors for its fiscal quarter ending in December of 2024.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 12.25M 1.34M Mar/2026
Agios Pharmaceuticals USD 13.75M 4.61M Mar/2026
Akebia Therapeutics USD 8.39M 12.8M Mar/2026
Alnylam Pharmaceuticals USD 126.63M 10.91M Mar/2026
Anika Therapeutics USD 6.34M 298K Mar/2026
Arrowhead Research USD 30.75M 2.19M Mar/2026
AstraZeneca USD 22.51B 2.78B Mar/2026
Bristol-Myers Squibb USD 4.23B 659M Mar/2026
Eli Lilly USD 5.03B 350M Mar/2026
Enanta Pharmaceuticals USD 1.88M 63K Dec/2025
Esperion Therapeutics USD 68.41M 3.34M Mar/2026
Halozyme Therapeutics USD 14.1M 6.8M Mar/2026
Heron Therapeutics USD 8.97M 24K Mar/2026
Insmed USD 73.38M 6.53M Mar/2026
J&J USD 10.46B 1.53B Mar/2026
Lexicon Pharmaceuticals USD 3M 87K Mar/2026
Ligand Pharmaceuticals USD 37.11M 33.87M Mar/2026
Merck USD 3.86B 541M Mar/2026
Minerva Neurosciences USD 640K 305K Dec/2025
Moderna USD 161M 156M Mar/2026
Novartis USD 4.46B 99M Dec/2025
Pfizer USD 4.51B 734M Mar/2026
PTC Therapeutics USD 25.48M 20M Mar/2026
Puma Biotechnology USD 6.39M 962K Sep/2025
Sangamo BioSciences USD 10.74M 7.46M Jun/2025
Sanofi EUR 22.71B 219M Mar/2026
Takeda JPY 491.34B 23.75B Mar/2026
Teva Pharmaceutical Industries USD 2.6B 65M Mar/2026
Ultragenyx Pharmaceutical USD 42M 11M Mar/2026
Vanda Pharmaceuticals USD 39.09M 33.28M Dec/2024
Veracyte USD 6.91M 2.32M Mar/2026